Rituximab has been found to be effective in severe systemic lupus erythematosus (SLE). Systemic lupus erythematosus is a long-term recurrent autoimmune disease, which can involve all systems and internal organs and lead to corresponding clinical symptoms. Rituximab is an immune-targeted drug that has recently been found to have some therapeutic effect on systemic lupus erythematosus, but the dosage cycle of using rituximab for the treatment of systemic lupus erythematosus is relatively longer, and it may take more than 3 months. Rituximab for the treatment of systemic lupus erythematosus belongs to the overdosage of drug instructions, should be used strictly under the guidance of a physician, the use of rituximab treatment common adverse drug reactions include bacterial infections, angioedema, leukopenia and so on. Patients who are allergic to the components of rituximab are prohibited from using the drug treatment. Attention to drug-induced infusion reactions may not be able to distinguish severe infusion reactions from allergic reactions or cytokine release syndrome. It is recommended that patients with systemic lupus erythematosus who need to be treated with rituximab should go to the rheumatology department of regular hospitals for detailed consultation and follow the doctor’s instructions for the use of medication.